Skip to main content
SpringerLink
Log in

Role of Matrix Metalloproteinase Inhibition in the Treatment of Pancreatic Cancer

  • Chapter
Pancreatic Cancer

Part of the book series: M. D. Anderson Solid Tumor Oncology Series ((MDA))

  • 233 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Landies S, Murray T, Bolden S, Wingo P. Cancer statistics 1999. J Am Cancer Soc. 1999;49:8–31.

    Google Scholar 

  2. Koshiba T, Wada M, Fujimot K, et al. Activation of MMP-2 and MMP-9 in human pancreatic cancer tissues and human pancreatic cancer lines. Gastroenterology. 1996;110:A545.

    Google Scholar 

  3. Mignatti P, Rifkin D. Biology and biochemistry of proteinases in tumor invasion. Phys Rev. 1993;73:161–195.

    CAS  Google Scholar 

  4. Sang Q. Complex role of matrix metalloproteinases in angiogenesis. Cell Res. 1998;8:171–177.

    CAS  PubMed  Google Scholar 

  5. Lozonschi L, Sunamura M, Kobari M, et al. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res. 1999;59:1252–1258.

    CAS  PubMed  Google Scholar 

  6. Eccles S, Box G, Court W, et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor Batimastat (BB-94). Cancer Res. 1996;56:2815–2822.

    CAS  PubMed  Google Scholar 

  7. Low J, Johnson M, Bone E, Dickson R, et al. The matrix metalloproteinase inhibitor Batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res. 1996;2:1207–1214.

    CAS  PubMed  Google Scholar 

  8. Watson S, Morris T, Robinson G, et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor Batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res. 1995;55:3629–3633.

    CAS  PubMed  Google Scholar 

  9. Wang X, Fu X, Brown P, et al. Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994;54:4726–4728.

    CAS  PubMed  Google Scholar 

  10. Davies B, Brown P, East N, et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 1993;53:2087–2091.

    CAS  PubMed  Google Scholar 

  11. Giavazzi R, Garofalo A, Ferri C, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res. 1998;4:985–992.

    CAS  PubMed  Google Scholar 

  12. Chirivi R, Garofalo A, Crimmin M, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer. 1994;58:460–466.

    CAS  PubMed  Google Scholar 

  13. Wojtowicz-Praga S, Torri J, Johnson M, et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol. 1998;16:2150–2156.

    CAS  PubMed  Google Scholar 

  14. Parsons S, Watson S, Steele R. Phase I/II trial of Batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Euro J Surg Oncol. 1997;23:526–531.

    CAS  Google Scholar 

  15. Zervos E, Shafii A, Rosemurgy A. Matrix metalloproteinase inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer. J Surg Res. 1999;81:65–68.

    Article  CAS  PubMed  Google Scholar 

  16. Zervos E, Shafii A, Haq M, et al. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro. J Surg Res. 1999;84:162–167.

    Article  CAS  PubMed  Google Scholar 

  17. Zervos E, Norman J, Gower W, et al. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res. 1997;69:367–371.

    Article  CAS  PubMed  Google Scholar 

  18. Zervos E, Franz M, Salhab K, et al. Matrix metalloproteinase inhibition improves survival in an orthotopic model of human pancreatic cancer. J Gastrointest Surg. 2000;4:614–619.

    Article  Google Scholar 

  19. Haq M, Shafii A, Zervos E, et al. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res. 2000;60:3207–3211.

    CAS  PubMed  Google Scholar 

  20. Rosemurgy A, Harris J, Langleben A, et al. Marimastat in patients with advanced pancreatic cancer: a dosefinding study. Am J Clin Oncol. 1999;22:247–252.

    Article  CAS  PubMed  Google Scholar 

  21. Burris H, Storniolo A. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer. 1997;33(suppl):S18–S22.

    CAS  PubMed  Google Scholar 

  22. Rosemurgy A, Buckels J, Charnley R, et al. A randomized study comparing Marimastat to gemcitabine as first-line therapy in patients with non-resectable pancreatic cancer. ASCO Proceedings, Philadelphia, Pa; 1999. Abstract 1005.

    Google Scholar 

Download references

Authors
  1. Alexander S. Rosemurgy II
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahmudul Haq
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA

    Douglas B. Evans M.D. (Professor of Surgery) & Peter W. T. Pisters M.D., F.A.C.S. (Associate Professor of Surgery) (Professor of Surgery) &  (Associate Professor of Surgery)

  2. Department of Gastrointestinal Medical Oncology, The University Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA

    James L. Abbruzzese M.D. (Professor of Medical Oncology, Chairman) (Professor of Medical Oncology, Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Rosemurgy, A.S., Haq, M. (2002). Role of Matrix Metalloproteinase Inhibition in the Treatment of Pancreatic Cancer. In: Evans, D.B., Pisters, P.W.T., Abbruzzese, J.L. (eds) Pancreatic Cancer. M. D. Anderson Solid Tumor Oncology Series. Springer, New York, NY. https://doi.org/10.1007/0-387-21600-6_35

Download citation

  • DOI: https://doi.org/10.1007/0-387-21600-6_35

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-95185-0

  • Online ISBN: 978-0-387-21600-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation